Earnings & Results
Omeros Posts $35.9 Million Q3 Revenue, Below FactSet Estimate, and Swings to Adjusted Earnings
By News Desk ·
Key takeaways
- Omeros reported third-quarter revenue of $35.9 million, missing the FactSet estimate of $37.3 million.
- YARTEMLEA net revenue rose 26% to $35.9 million in the quarter.
- Omeros recorded a GAAP net loss of $57.4 million, or $0.79 per share, including a $62.0 million non-cash derivative remeasurement charge.
Omeros reported third-quarter revenue of $35.9 million, missing the FactSet estimate of $37.3 million, and swung to adjusted earnings, MarketScreener reported on November 16, 2026. The company's stock closed at $16.68, down 4.63% from the prior close.
Omeros Swings to Adjusted Profit as YARTEMLEA Sales Climb
Omeros is a commercial-stage biopharmaceutical company that develops therapies for complement-mediated diseases, central nervous system disorders and oncology, and sells YARTEMLEA, which it describes as the only FDA-approved therapy for TA-TMA, according to company records.
YARTEMLEA net revenue rose 26% to $35.9 million in the quarter, TradingView reported. Omeros posted a GAAP net loss of $57.4 million, or $0.79 per share, which included a $62.0 million non-cash derivative remeasurement charge. Operating cash flow was $13.3 million, and the company held $95.3 million in cash and short-term investments.
MarketScreener reported that Omeros swung to adjusted earnings in the quarter and did not disclose further details on the adjusted figure.
YARTEMLEA Billing and Launch Figures
Omeros launched YARTEMLEA commercially in the US on January 2, 2026, and reached cash-flow positivity in the first quarter of 2026 with 30 accounts ordering product and $9.89 million in first-quarter sales, according to akta.pro company records. CMS assigned a permanent HCPCS J-code, J1289, for YARTEMLEA effective July 1, 2026, which the records describe as streamlining Medicare and commercial payer billing and reimbursement at the $36,000 per-vial price point.
EMA Opinions and a Securities Investigation
Pomerantz LLP is investigating Omeros for potential securities fraud following two European Medicines Agency negative opinions on its narsoplimab marketing authorisation application, GlobeNewswire reported. The stock fell 19.12% to $8.67 after the first negative opinion and 13.78% to $16.20 after a re-examination.
Omeros announced on November 10, 2026, that it would report third-quarter results after market close on November 16 and host a conference call and webcast at 4:30 p.m. Eastern Time, FinancialContent Business Page reported.
Omeros Pipeline Timeline
Omeros said its OncotoX-AML cancer therapeutic platform achieved up to 99% reduction in myeloid progenitor cells in nonhuman primate studies and is advancing to IND-enabling studies, with a first-in-human trial targeted for late 2027, according to its announcement.